This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Sustained use of CPAP slows deterioration of cognition, sleep, and mood in patients with Alzheimer’s disease and obstructive sleep apnea: a preliminary study
Cooke, Jana R.,
Ayalon, Liat,
Palmer, Barton W.,
Loredo, Jose S.,
Corey-Bloom, Jody,
Natarajan, Loki,
Liu, Lianqi,
Ancoli-Israel, Sonia
Introduction: Obstructive sleep apnea (OSA) is common among patients with Alzheimer’s disease (AD). Untreated OSA exacerbates the cognitive and functional deficits. Continuous positive airway pressure (CPAP) has recently been shown to have beneficial effects on cognition in AD. Little attention has focused on the long-term benefits of CPAP in these patients.; Methods: This was an […]
Continuous positive airway pressure deepens sleep in patients with Alzheimer’s disease and obstructive sleep apnea
Cooke, Jana R.,
Ancoli-Israel, Sonia,
Liu, Lianqi,
Loredo, Jose S.,
Natarajan, Loki,
Palmer, Barton S.,
He, Feng,
Corey-Bloom, Jody
Objective: Patients with Alzheimer’s disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in AD patients with OSA.; Methods: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks […]
An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration
Boxer, Adam L.,
Lipton, Anne M.,
Womack, Kyle,
Merrilees, Jennifer,
Neuhaus, John,
Pavlic, Danijela,
Gandhi, Anisha,
Red, Dana,
Martin-Cook, Kristen,
Svetlik, Doris,
Miller, Bruce L.
There are currently no Food and Drug Administration-approved treatments for frontotemporal lobar degeneration (FTLD). The objectives of this study were to explore the tolerability of memantine treatment in FTLD and to monitor for possible effects on behavior, cognition, and function. Forty-three individuals who met clinical criteria for FTLD [21 with frontotemporal dementia (FTD), 13 with […]
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease
Beglinger, Leigh J.,
Adams, Williams H.,
Paulson, Henry,
Fiedorowicz, Jess G.,
Langbehn, Douglas R.,
Duff, Kevin,
Leserman, Anne,
Paulsen, Jane S.
Background: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder.; Methods: Twenty participants with mild Huntington disease who complained of inattention were randomized to receive […]
Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial
Barnes, Deborah E.,
Yaffe, Kristine,
Belfor, Nataliya,
Jagust, William J.,
DeCarli, Charles,
Reed, Bruce R.,
Kramer, Joel H.
We performed a pilot randomized, controlled trial of intensive, computer-based cognitive training in 47 subjects with mild cognitive impairment. The intervention group performed exercises specifically designed to improve auditory processing speed and accuracy for 100 min/d, 5 d/wk for 6 weeks; the control group performed more passive computer activities (reading, listening, visuospatial game) for similar […]
Effect of music on pain for home-dwelling persons with dementia
The purpose of this study was to investigate the effect of music on pain for home-dwelling persons with dementia. A quasiexperimental design was used. Fifteen subjects listened to their preferred music for 30 minutes before peak agitation time, for 2 days per week, followed by no music for 2 weeks. The process was repeated once. […]
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Olin, Jason T.,
Bhatnagar, Vinod,
Reyes, Patricio,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]
Hospice use and outcomes in nursing home residents with advanced dementia
Objectives: To identify characteristics of nursing home (NH) residents with advanced dementia and their healthcare proxies (HCPs) associated with hospice referral and to examine the association between hospice use and the treatment of pain and dyspnea and unmet needs during the last 7 days of life.; Design: Prospective cohort study.; Setting: Twenty-two Boston-area NHs.; Participants: […]
Errorless practice as a possible adjuvant to donepezil in Alzheimer’s disease
Rothi, Leslie J. Gonzalez,
Fuller, Renee,
Leon, Susan A.,
Kendall, Diane,
Moore, Anna,
Wu, Samuel S.,
Crosson, Bruce,
Heilman, Kenneth M.,
Nadeau, Stephen E.
Six individuals with probable Alzheimer’s disease (AD) participated in a phase 1 study employing a repeated measures, parallel baseline design testing the hypothesis that error-free experience during word production practice combined with an acetyl cholinesterase inhibitor would improve confrontation naming ability. While acetyl cholinesterase inhibitors are safe and delay cognition decline associated with AD, improvement […]